Zydus Cadila starts human trails of COVID-19 vaccine ZyCoV-D
Speaking on the development, Chairman, Zydus Cadila, Mr. Pankaj R. Patel said, "This is an all-important step in our fight against COVID-19. We acknowledge the support of the National Biopharma Mission, BIRAC, Department of Biotechnology, Govt. of India, and regulatory agencies ICMR and DCGI in the development of the ZyCoV-D vaccine candidate. We look forward to the Adaptive Phase I/II clinical studies and gathering important data on ZyCoV-D in the months ahead."
Ahmedabad: Zydus, an innovation-driven global healthcare company, has announced that the Adaptive Phase I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D has commenced with the first human dosing.
The Adaptive Phase I/II dose-escalation, the multi-centric study will assess the safety, tolerability, and immunogenicity of the vaccine. The human dosing of the vaccine marks a key milestone since the launching of the accelerated vaccine development program for COVID-19 in February 2020.
Also Read: Zydus Cadila COVID-19 Vaccine Gets DCGI Nod For Human Clinical Trials
Speaking on the development, Chairman, Zydus Cadila, Mr. Pankaj R. Patel said, "This is an all-important step in our fight against COVID-19. We acknowledge the support of the National Biopharma Mission, BIRAC, Department of Biotechnology, Govt. of India, and regulatory agencies ICMR and DCGI in the development of the ZyCoV-D vaccine candidate. We look forward to the Adaptive Phase I/II clinical studies and gathering important data on ZyCoV-D in the months ahead."
In the Adaptive Phase I/ II clinical trials, Zydus will be enrolling over 1000 subjects across multiple clinical study sites in India. The Company has already manufactured clinical GMP batches of the vaccine candidate for the clinical trials.
Also Read: COVID-19 Drug: Zydus Cadila Gets Mexican Nod To Test Desidustat
